Business Context and Reporting Period
ImmunityBio, Inc. (IBRX) filed a Form 8-K Current Report on January 23, 2026. The filing discloses the entry into a material definitive agreement regarding the company's outstanding debt obligations.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, or operating margins. The primary financial metric disclosed is the outstanding principal amount of the Convertible Promissory Note, which is $505.0 million.
Material Changes
On January 23, 2026, the Company entered into a letter amendment to its Second Amended and Restated Promissory Note dated December 10, 2024, held by Nant Capital, LLC (an entity affiliated with Executive Chairman Dr. Patrick Soon-Shiong). The material change is the addition of a partial conversion feature. Previously, the note did not allow for partial conversion; the amendment now permits the Holder to convert any portion of the outstanding principal into fully paid and nonassessable shares of common stock at any time prior to the maturity date. No other terms were altered.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or discussion of general business risks. The primary contingency noted is the potential dilution of existing shareholders if the Holder exercises the new right to partially convert the $505.0 million debt into equity.
Investor Verification Checklist
- Verify the specific conversion price or formula for the $505.0 million Convertible Promissory Note in the full text of Exhibit 10.1.
- Confirm the maturity date of the Convertible Promissory Note to assess the timeline for potential conversion.
- Review the Company's current cash position to determine if the debt remains a near-term liquidity priority.
- Assess the potential dilution impact on existing shareholders if the Holder converts the full or partial principal amount.